The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/activity in head and neck squamous cell carcinoma (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yinwen, Borcherding, Nicholas, Ogunsakin, Ayomide, Lemke-Miltner, Caitlin D., Gibson-Corley, Katherine N., Rajan, Anand, Choi, Allen B., Wongpattaraworakul, Wattawan, Chan, Carlos H. F., Salem, Aliasger K., Weiner, George J., Simons, Andrean L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810827/
https://www.ncbi.nlm.nih.gov/pubmed/33452311
http://dx.doi.org/10.1038/s41598-020-80957-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810827/
https://www.ncbi.nlm.nih.gov/pubmed/33452311
http://dx.doi.org/10.1038/s41598-020-80957-z

Ejemplares similares